Skip to content
Search AI Powered

Latest Stories

Massachusetts State Lawmakers Release Scathing Critique of MA's Cannabis Control Commission

There has been endless drama around the Massachusetts Cannabis Control Commission over the past few months, all of which is only heightening in the wake of state Treasurer Deb Goldberg suspending the agency’s chairwoman last week.

Talking Joints Memo - Chris Faraone
Talking Joints Memo - Chris Faraone

By Chris Faraone, Talking Joints Memo. Reprinted with permission from Talking Joints Memo. .

“The public deserves some accountability on why these issues have proven so hard to stamp out, and what long-term changes the agency is making to get its work done with more transparency and efficiency.”

There has been endless drama around the Massachusetts Cannabis Control Commission over the past few months, all of which is only heightening in the wake of state Treasurer Deb Goldberg suspending the agency’s chairwoman last week.


The latest major news comes not directly from the Worcester-based commission, but rather from Beacon Hill, where a bipartisan group of five state lawmakers released a scathing letter to the chairs of the legislature’s Joint Committee on Cannabis Policy this morning. 

The critique arrives a day before the House and Senate body meets on Tuesday for a hearing on bills ranging from An Act relative to cannabis use by first responders, to An Act relative to employment protections for medical marijuana patients, to An Act relative to cannabis research funding.

As the office of state Sen. Michael Moore, which released the letter, explained: “In light of mounting reports of scandal and dysfunction at the Massachusetts Cannabis Control Commission (CCC), five members of the Massachusetts Legislature today sent a letter to the Joint Committee on Cannabis Policy requesting an oversight hearing to bring better transparency and accountability to the agency. The effort, led by Senator Michael Moore, comes after the Chair of the CCC described the agency as ‘in crisis.’”

Furthermore, “the letter, signed by three Senators and two Representatives, asks for an oversight hearing that addresses seven primary points of dysfunction at the CCC.” They are:

-Suspension of Chair O’Brien; State Treasurer Deborah Goldberg suspended CCC Chair Shannon O’Brien, according to media reports. The Treasurer’s Office has so far declined to explain the suspension or name an interim chair.

-Ongoing Governance Issues; the CCC has been engaged in a series of closed-door mediation sessions over its governance structure since April 2022.

-Licensing Delays; opaque and lengthy licensing processes have become a frequent complaint to legislators’ offices.

-Extended and Overly Aggressive Investigations; investigators from the CCC have been criticized for operating in an overly aggressive and unproductive manner during site visits, with little communication to business owners about their investigation status or findings.

-Inadvertent Records Release; in spring 2023, the CCC allegedly shared a document containing the names, addresses, phone numbers, emails, and other sensitive personal information of every cannabis worker, active or inactive, in Massachusetts.

-Alleged Retaliation Against an Independent Journalist; CCC officials allegedly cited the content of a journalist’s testimony before the Joint Committee on Cannabis Policy as part of the justification for stripping the journalist of their press credentials.

-Sex Offenders as Retail and Delivery Operator Agents; following the passage of legislation in 2022, the CCC has proposed allowing registered sex offenders to become retail and delivery operators in the cannabis industry, positions that will allow them access to sensitive customer information.

Among their gripes, the authors of the letter notes how “the CCC has engaged in semi-regular executive session mediation,” writing: “As the public is excluded from executive session, the specific items discussed in the mediation, its progress and status are all unclear. … As the Open Meeting Law makes clear, these issues are not intended to remain behind closed doors forever, and ultimately are expected to be resolved publicly.”

Regarding the CCC’s process of impugning licensees, the letter recognizes how “investigations have also come under criticism for operating in an overly aggressive, unproductive, and untimely manner,” and asks, among other questions: “What are the CCC’s policies and procedures for conducting its investigations? How were these policies and procedures developed and what type of training does the CCC provide to its investigators?”

The letter also questions the agency’s decision to shut out blogger Grant Smith-Ellis, writing, “It is extremely concerning that the CCC finds itself leveraging the content of testimony before the Committee as part of the rational [sic] to exclude certain media oversight. Particularly since the journalist had testified in favor of legislation that would have created an independent oversight unit for the CCC. The chilling effect it will have on future testimony alone is enough to warrant action by the Committee.” Adding, “it is bewildering that an agency with a troubled governance structure, vacancies in several leadership positions, and issues in the licensing, investigation, and public records process would decide that an independent journalist doesn’t meet certain media standards rather than first addressing its own internal issues.”

“Since its creation in 2017, The Cannabis Control Commission has faced what sometimes feels like an endless stream of scandals. The public deserves some accountability on why these issues have proven so hard to stamp out, and what long-term changes the agency is making to get its work done with more transparency and efficiency,” Sen. Moore said in a statement. “Especially considering the 23% funding increase the CCC requested during FY24 budget negotiations, it is now more critical than ever that we make sure this agency has a plan to right the ship. Millions of our tax dollars are at stake – I am hopeful the Joint Committee on Cannabis Policy will schedule a hearing to get answers from the top brass at the CCC.”

Read the whole letter here.

More For You

map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report byThe New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy

Selective Outrage Hurts NY Cannabis

Authored by: Veterans Holdings CEO Jason Ambrosino

Last week, the New York Medical Cannabis Industry Association (NYMCIA) issued a press release accusing licensed dispensaries of selling "out-of-state cannabis" and undermining the integrity of the legal market. Read the press release here.

Keep ReadingShow less
image of a circle of doctors and surgeons standing over and looking at a patient on operating room table
New Study Confirms Medical Cannabis Benefits in Cancer Care—Time for Policy to Catch Up
Photo by National Cancer Institute on Unsplash

Cannabis & Cancer: The Evidence Is In—So Why Is the Medical Establishment Still Dragging Its Feet?

If you've ever watched a loved one battle cancer—or been on that journey yourself—you already know the harsh truth: the pain is real, the nausea is relentless, the appetite is gone, and the side effects of treatment often feel worse than the disease. So when patients say cannabis helps, it shouldn’t take 10,000 studies for the medical community to take them seriously.

And yet, here we are.

Keep ReadingShow less
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Giphy

Aging & Cannabis: New Findings

For decades, cannabis has been widely regarded as a substance with potential cognitive risks, particularly when used over long periods. Governments across the globe have classified it as a controlled substance, citing concerns about the effects of marijuana use, including memory loss, diminished executive function, and long-term neurological impact. But new research is challenging this long-standing assumption, suggesting that cannabis use may not be linked to age-related cognitive decline—and might even be associated with better cognitive preservation over time.

A recent study published in PubMed (NIH, 2024) followed over 5,000 men for more than four decades to analyze the long-term cognitive effects of cannabis use. The results? Men with a history of cannabis use experienced less cognitive decline from early adulthood to late midlife compared to those who never used cannabis.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less